QP Wealth Management LLC Purchases Shares of 8,816 Astrazeneca Plc $AZN

QP Wealth Management LLC acquired a new position in Astrazeneca Plc (NYSE:AZN) during the 4th quarter, HoldingsChannel reports. The fund acquired 8,816 shares of the company’s stock, valued at approximately $810,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in AZN. Triumph Capital Management acquired a new position in shares of Astrazeneca in the 3rd quarter valued at $25,000. Rakuten Investment Management Inc. acquired a new stake in Astrazeneca during the third quarter valued at $31,000. JPL Wealth Management LLC acquired a new stake in Astrazeneca during the third quarter valued at $35,000. E Fund Management Hong Kong Co. Ltd. increased its holdings in Astrazeneca by 144.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock valued at $36,000 after buying an additional 275 shares in the last quarter. Finally, Abound Wealth Management increased its holdings in Astrazeneca by 1,767.9% in the third quarter. Abound Wealth Management now owns 523 shares of the company’s stock valued at $40,000 after buying an additional 495 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Astrazeneca Stock Down 2.9%

Shares of Astrazeneca stock opened at $183.40 on Friday. The stock has a market capitalization of $284.44 billion, a P/E ratio of 28.00, a P/E/G ratio of 1.42 and a beta of 0.32. Astrazeneca Plc has a twelve month low of $122.48 and a twelve month high of $212.71. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.72 and a current ratio of 0.94.

Astrazeneca Dividend Announcement

The company also recently announced a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be given a $1.595 dividend. This represents a dividend yield of 156.0%. The ex-dividend date is Friday, February 20th. Astrazeneca’s dividend payout ratio (DPR) is 66.26%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on AZN shares. Citigroup began coverage on shares of Astrazeneca in a research note on Tuesday, January 27th. They set a “buy” rating on the stock. Morgan Stanley restated an “overweight” rating and issued a $103.00 price target on shares of Astrazeneca in a research note on Wednesday, December 3rd. HSBC reaffirmed a “buy” rating and issued a $108.00 price target on shares of Astrazeneca in a report on Wednesday, December 10th. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday. Finally, Guggenheim restated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, December 3rd. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $95.75.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.